HLA-B基因多态性的卡马西平个体化用药临床研究分析  

Clinical analysis of Individualized use of carbamazepine with HLA-B gene polymorphism

作　　者：董秀 向倩[1] 王梓凝[1] 胡琨[1] 谢秋芬[1] 周颖[1] 崔一民[1,2,3] DONG Xiu;XIANG Qian;WANG Zi-ning;HU Kun;XIE Qiu-fen;ZHOU Ying;CUI Yi-min(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Institute of Clinical Pharmacology,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学第一医院,药学部,北京100034 [2]北京大学第一医院,临床药理研究所,北京100034 [3]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国临床药理学杂志》2022年第13期1549-1552,1557,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家重大新药创制基金资助项目(2018ZX09201014-003,2017ZX09101001);国家自然科学基金资助项目(81872940,82073935,81973395);北京市科学技术委员会医药创新品种研发培育及产业支撑平台能力建设基金资助项目(Z191100007619038)。

摘　　要：人类白细胞抗原B(HLA-B)基因多态性对卡马西平的用药风险有重要影响,携带HLA-B*15:02等位基因的患者在使用卡马西平时,发生严重皮肤不良反应如史蒂文斯-约翰逊综合征和中毒性表皮坏死溶解的风险更高。临床推荐在使用卡马西平之前应当进行基因检测,明确是否携带HLA-B*15:02等位基因,从而进行个体化用药,降低发生严重不良反应的风险。本研究分析了HLA-B基因与卡马西平用药之间的关系,综述了基于HLA-B基因多态性的卡马西平个体化药物治疗现状,整理并总结相关指导意见;同时综述了HLA-B基因在中国使用卡马西平的患者中的相关研究,总结分析卡马西平用于中国患者时的用药风险,为中国患者为精准治疗策略的优化提供参考。Human leukocyte antigen B(HLA-B) gene polymorphism has an important effect on the risk of carbamazepine use. Carriers of HLA-B*15:02 alleles may increase the risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis. Clinical genotyping tests can be used to examine the presence of the HLA-B*15:02 allele, the test results may help clinicians to adjust carbamazepine therapy. This article summarized the relationship between HLA-B gene and carbamazepine, reviewed the progress of individualized drug therapy of carbamazepine based on HLA-B gene polymorphism. Relevant guidelines were sorted out to provide reference for the optimization of anti-epileptic therapy strategies. Besides, we reviewed relevant studies on patients with HLA-B gene treated with carbamazepine in China, and summarized and analyzed the drug risk of carbamazepine in Chinese patients, so as to provide reference for the optimization of precision therapy strategies for Chinese patients.

关 键 词：人类白细胞抗原B 卡马西平 个体化治疗 

分 类 号：R97[医药卫生—药品]